topotecan has been researched along with cabazitaxel in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chadjaa, M; Cho, BC; Evans, TL; Fischer, JR; Martinez, P; Ramlau, R; Shen, L; Shepherd, FA; Syrigos, KN; Udud, K; Wolf, M | 1 |
Beaumont, H; Chadjaa, M; Evans, TL; Guermazi, A; Hong, SR; Klifa, C; Monostori, Z | 1 |
2 trial(s) available for topotecan and cabazitaxel
Article | Year |
---|---|
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2015 |
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden | 2018 |